Jonathan Behrens, MD
Adult Reconstructive Orthopaedic Surgery · Webster, TXNPI 1790214195
Payments from drug & device makers
What this record shows
This record is dominated by education: $11,274 of the $13,443 with a category attached, or 83.9%. Smith+Nephew accounts for 75.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $5,842 and has fallen 91.1% since, to $521 in 2025. That places this record below the midpoint for adult reconstructive orthopaedic surgery clinicians in TX, where the typical reported total is $14,244.
Across 25 payments — averaging $537.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$10K
- Stryker$2K
- Elite Orthopedics, LLC$1K
- Medacta USA, Inc.$110
- BD$78
- Heron Therapeutics, Inc.$24
- plus $16 from 1 others
What the payments were for
- Food & beverage$2,16916%
- Education$11,27484%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 3 | $10,077 |
| Stryker | 16 | $1,864 |
| Elite Orthopedics, LLC | 1 | $1,274 |
| Medacta USA, Inc. | 1 | $110 |
| BD | 2 | $78 |
| Heron Therapeutics, Inc. | 1 | $24 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,443 in reported general payments places this provider in the 45th percentile of 86 adult reconstructive orthopaedic surgery providers in Texas.
See all adult reconstructive orthopaedic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 103 | $4,118 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 141 | $1,093 |
| Doxycycline Hyclate | 85 | $1,017 |
| Methocarbamol | 74 | $446 |
| Tramadol Hcl | 86 | $337 |
| Meloxicam | 50 | $123 |
| Gabapentin | 13 | $109 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $105 |
| Tizanidine Hcl | 17 | $68 |
| Amoxicillin | 17 | $22 |
Paid to pharmacies, not to this prescriber.
Other adult reconstructive orthopaedic surgery in Webster
- Kenneth BrooksWebster$17K
- Tyler GoldbergAustin$4.6M
- Antonia ChenDallas$3.8M
- John BarringtonPlano$2.2M
- Roger EmersonPlano$691K
- Donald HohmanDallas$537K
- Steven WeedenFort Worth$370K
- Marcus FordFort Worth$296K
- Raul MarquezEdinburg$278K
- Richard ReitmanPlano$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.